Spectranetics Company Profile

18:41 EDT 18th June 2018 | BioPortfolio

Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in multiple, minimally invasive cardiovascular procedures. This technology treats complex cardiovascular conditions by vaporizing lipid-based, calcified and fibrotic plaque, saphenous vein graft disease, and neointimal hyperplasia. Excimer laser is also used to remove scar tissue holding problematic pacemaker and defibrillator cardiac leads in place. The Company’s disposable catheters use high-energy “cool” ultraviolet light to vaporize blockages into tiny particles that are easily absorbed into the blood stream, reducing complications and improving clinical outcomes. Excimer Laser Ablation System Over 600 laser ablation systems are installed worldwide, with nearly 500 in the United States. Catheter Products Spectranetics’ offers laser ablation for peripheral intervention, coronary intervention, and lead removal (ablating the scar tissue holding problematic pacemaker and defibrillator leads in place) Peripheral Intervention: TURBO elite™ laser ablation catheters Coronary Intervention: ELCA® laser ablation catheters Lead Removal: SLS ® II laser ablation catheter Crossing Devices: Quick-Cross® support catheters Clinical Trials On March 14, 2007 enrollment was completed in the FDA-approved CELLO Trial. The trial was designed to provide clinical data on the reduction of arterial blockages in above the knee arteries following the use of our TURBO-Booster™ product, a non-laser based product used in conjunction with TURBO elite laser ablation catheters. The TURBO-Booster product is designed to facilitate laser ablation of larger diameter arteries above the knee. We believe that approximately two-thirds of the estimated 400,000 endovascular procedures performed annually in the U.S. are performed on above the knee blockages. The CELLO Trial data will be gathered and the 510(k) application is currently expected to be filed with the FDA in Q2 2007. History Spectranetics was founded in 1984 by Robert Golobic, Ph.D., a United States Air Force physicist and Johan Sverdrup, a Hewlett-Packard engineer. Golobic had been working on lasers as part of the Strategic Defense initiative and Sverdrup had done ultrasound work with ADR (Advanced Diagnostic Research) and Doppler imaging with Vingmed. Together they created Spectranetics – one of the first companies in the world to explore the possibility of using a “cool” ultraviolet laser to clear occluded arteries. The first patient was treated at the Texas Heart Institute in 1989.


96 Talamine Court
Colorado Springs
United States of America


Phone: 1-800-231-0978
Fax: 1-719-633-8791

News Articles [2 Associated News Articles listed on BioPortfolio]

AtriCure Names Scott Drake Board Chairman

Richard Johnston and Elizabeth D. Krell, Ph.D. are Retiring from the Board of Directors in May AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical tre...

Global and Europe Medical Laser Systems Market Status and Future Forecast 20132023 [Report Updated: 10012018] Prices from USD $3500

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPar...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Study to Evaluate the Safety and Performance of Spectranetics Laser w/Adjunct PTA and Gore Viabahn Endoprosthesis for Treatment of SFA Instent Restenosis

A Multicenter study to evaluation the safety and performance of Spectranetics Laser with Adjunct PTA and Gore Viabahn Endoprosthesis for the Treatment of SFA Instent Restenosis

Prime Time for Superficial Femoral Artery (SFA) - The SFA Study

The purpose of this study is to compare the different endovascular treatment modalities for the femoropopliteal segment, and to determine technical success, efficacy and patency at mid-ter...

Bridge Occlusion Balloon in Lead Extraction Procedure

To evaluate the use of an occlusion balloon (Bridge™ Occlusion Balloon, Spectranetics) within the Superior Vena Cava in lead extraction patients.

Companies [0 Results]


More Information about "Spectranetics" on BioPortfolio

We have published hundreds of Spectranetics news stories on BioPortfolio along with dozens of Spectranetics Clinical Trials and PubMed Articles about Spectranetics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Spectranetics Companies in our database. You can also find out about relevant Spectranetics Drugs and Medications on this site too.

Quick Search


Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Corporate Database Quicklinks

Searches Linking to this Company Record